You are here

Funding

Active Funding:

1R21CA229027 - NCI IMAT Program

 

XCELL Biologix 

 

The Ohio State University Comprehensive Cancer Center 

 

Completed/Past Funding:

Grant Number: W81XWH-15-9-001

Source: s/RegenMed Development Organization (ReMDO) via MTEC

Title: Development of a Universal Bioink with Tunable Mechanical Properties for Regenerative Medicine Additive Manufacturing of Clinical Products

Role: PI

Performance Period: 11/04/2016 – 10/30/2021

Annual Direct Costs: $637,486

Time Commitment: 1.8 calendar months (15% effort)

Goal: To develop and engineer a modular system allowing for customization of bioink biomaterials for bioprinting that can be deployed in all common bioprinting hardware modalities and be tailored to create and support the majority of the tissue types in the human body – both for regenerative applications and organoid technologies for diagnostics, personalized medicine, and drug development.

 

Grant Number: n/a

Source: Wake Forest Breast Cancer Center of Excellence

Title: An Immuno-Organoid Platform for ex vivo Testing of Novel Immunotherapies for TNBC Patients 

Role: PI

Performance Period: 1/01/2019 – 12/31/2019

Annual Direct Costs: $100,000

Time Commitment: 0.6 calendar months (5% effort)

Goal: Utilize parallel murine models and murine organoid triple negative breast cancer models to direct immune-enhancing of patient-derived breast cancer tumor organoids and subsequent techniques to reduce immune-suppression in triple negative breast cancer, enabling immune checkpoint blockade therapies.

 

Grant Number: n/a

Source: Myeloma Crowd Foundation

Title: Rapid and Personalized Prediction of Myeloma Response to Chemotherapy Using CD Organoids

Role: Co-PI

Performance Period: 1/01/2019 – 12/31/2019 (option to renew)

Annual Direct Costs: $150,000

Time Commitment: 1.2 calendar months (10% effort)

Goal: Develop supportive microenvironment conditions to support difficult to maintain ex vivo myeloma cell populations. Deploy organoids created in personalized chemosensitivity screening studies and correlate with patient outcomes.

 

Grant Number: n/a

Source: Wake Forest Clinical and Translational Science Institute

Title:    A tunable thixotropic hydrogel bioink for bioprinting of functional tissue analogs                           

Performance Period: 4/01/2018 – 3/31/2019

Role: PI

Annual Direct Costs: $40,000

Time Commitment: no salary

Goal: We propose to employ, query, and quantify the contributions of inter-polymer/protein forces (hydrogen bonding versus covalent bonding) in generating thixotropic hydrogel bioinks, subsequently assessing how these forces influence bioprinting parameters during tissue construct biofabrication. We will characterize and optimize contributions of non-covalent, hydrogen bond-based interactions within thixotropic extracellular matrix (ECM)-based hydrogel bioinks. Subsequently we will employ and validate bioinks by bioprinting viable and functional tissue constructs (liver construct and heart patch).

 

Grant Number: n/a

Source: Comprehensive Cancer Center at Wake Forest Baptist

Title:    Patient tumor-derived tumor-on-a-chip technology for determining metastatic potential and response to chemotherapy prior to initiation of treatment                                             

Role: PI

Performance Period: 5/01/2017 – 11/30/2019

Annual Direct Costs: $10,000

Time Commitment: no salary

Goal: Employ genetic screening to identify drugable biomarkers in patient gastrointestinal tumor biopsies. Use cells from these biopsies to create 3D tumor organoids with which to test biomarker-driven drugs for efficacy for each patient case.

 

Grant Number: 2017-614-001

Source: Medical Technology Enterprise Consortium (MTEC)

Title: Pre-clinical Assessment of Bioprinted Human Skin for Wound Healing and Skin Regeneration

Role: Co-I

Performance Period: 11/28/2017 – 11/19/2018

Annual Direct Costs: $193,548

Time Commitment: 0.84 calendar months (7% effort)

Goal: The overall goal of the project is to bioprint full-thickness human skin with hair follicle appendages, microvasculature, immune cells and pigmentation and use it as a skin graft in immunodeficient rats.

 

Grant Number: 1 R33 CA202822-01

Source: NIH

Title: Bioengineered Lung Tumor Organoids for Development of Personalized Medicine

Role: Co-I

Performance Period: 04/12/2016 – 03/31/2019

Annual Direct Costs: $248,983

Time Commitment: 0.96 calendar months (8% effort)

Goal: Personalized oncology, whereby tumor DNA is sequenced to identify actionable gene mutations, is poised to become a standard process in cancer treatment,but is dependent on the availability of sufficient amounts of intact tumor cell DNA. We propose to bioprint lung organoids that will recapitulate the in vivo lung microenvironment in order to successfully expand a small number of freshly isolated lung cancer cells in vitro.

 

Grant Number: W81XWH-13-2-0054

Source:  DOD USAMRAA                                                                                            

Title: Amniotic Fluid-Derived Stem Cells for Enhanced Wound Healing

Role: Co-I

Performance Period: 09/23/2013 – 09/22/2019 (NCE)

Annual Direct Costs: $0

Time Commitment: 2.64 calendar months (22% effort)

Goal: The goal of this work is to develop a method that will permit the use of allogeneic source of fetal stem cells, and novel hydrogels for clinical management of burn wounds, allowing wound healing treatment to achieve fast and comprehensive wound coverage that results in functional and cosmetically superior skin.

 

Grant Number: 1 R21 CA28933-01A1  

Source:  NIH

Title:  Development of a CF10 Predictive Gene Signature in CRC Organoids

Role: Co-I                                                       

Performance Period: 02/02/2018 – 01/31/2020

Annual Direct Costs: $130,000

Time Commitment: 0.96 calendar months (8% effort)

Goal: This project investigates whether a new polymeric fluoropyrimidine, CF10, is effective for treating colorectal cancer (CRC) that is non-responsive to 5-fluorouracil (5-FU). Our preliminary studies show CF10 is much more potent than 5-FU and is effective in models of CRC sub-types that are non-responsive to 5-FU. We will systematically evaluate response of CRC cells and patient tumors using novel tumor organoid technology to establish in what CRC sub-types CF10 treatment provides a therapeutic advantage.

 

Title:  INtegrated Organoid Testing System, (INGOTS)  

Role: Co-I

Supporting Agency:  Defense Threat Reduction Agency/SPAWAR

Performance Period: 03/28/2013 – 10/01/2018

Level of Funding (total costs):  $17,750,269

Goals: INGOTS will be comprised of four interconnected microscale bioreactors, each containing fully-functional, three dimensional (3D) human tissue constructs (organoids). INGOTS will allow for the application of test agents at the individual organoid or whole body system level and will employ both commercially available human cells and blood substitutes.

 

Title:  Patient-specific 3D tumor organoids for glioblastoma multiforme precision medicine           

Role: Principal Investigator

Supporting Agency:  Wake Forest Brain Tumor Center of Excellence

Performance Period: 05/01/2016 – 06/30/2017

Level of Funding (total costs):  $30,000

Goals: The goal is to demonstrate and implement a GBM organoid system within the framework of clinical precision medicine, by demonstrating biomarker- and mutation-based drug targeting in 3D patient-derived GBM tumor models. To accomplish this goal, patient-derived GBM organoids will be fabricated, and genetic profiles will be used to inform customized drug screening. These customized GBM treatments will be assessed for responsiveness using quantitative analysis of tumor growth, reduction, and migration in 3D space, and viability/apoptosis.

 

Title: Patient-specific Bioengineered Lung Tumor Organoids to support personalized medicine

Role: Co-Investigator

Supporting Agency:  Center for Public Health Genomics

Performance Period: 08/01/2015 – 08/01/2016

Level of Funding (total costs):   $25,000

Goal: To employ bioprinted lung organoids to support growth of non-small cell lung cancer biopsies in order to increase cellular yield that can be used for genetic screens for precision medicine.

 

Title:  A Three-Dimensional Liver Microtumor Organoid Platform for Anti-Cancer Drug Development

Role: Principal Investigator

Supporting Agency:  Golfers Against Cancer

Performance Period: 03/01/2013 – 03/01/2015

Level of Funding (total costs):  $40,000

Goals:  In a rotating bioreactor, liver organoids will be created, inside of which reside metastatic colon carcinoma cells. In this 3-D environment, cancer cells behave as they would when in the body, providing a superior human cell-based in vitro testing platform for screening potential drug candidates in comparison to traditional 2-D cultures or animals.

 

Title:  CTSI Translational Pilot - A patient-specific tumor-on-a-chip platform for screening precision medicine-driven therapies

Role: Principal Investigator

Supporting Agency:  Wake Forest Baptist Medical Center – Clinical and Translational Science Institute

Performance Period: 02/01/2016 – 04/01/2017

Level of Funding (total costs):  $40,000

Goals: To demonstrate the utility of using tumor models created using cells from actual patient tumor biopsies to screen drug therapies for a given patient, thereby identifying the most effective treatment. Single colorectal cancer tumor organoids are created within colon constructs and screened using drugs commonly employed against colorectal cancer.

 

Title:  WFIRM – Promoting Innovative Discoveries – Intramural Pilot Funding Program    

Role: Principal Investigator

Supporting Agency:  Wake Forest Institute for Regenerative Medicine

Performance Period: 10/01/2014 – 10/01/2015

Level of Funding (total costs):  $25,000

Goals: To merge microfluidic device technology with photo-patterned hydrogel biomaterials to create a high-throughput system of 3-D tumor and tissue organoids for drug testing and metastasis exploration. Initial pilot work focuses on colon carcinoma metastases in liver organoids. Post-pilot work will expand to other tissue/tumor types and the biological mechanisms that play important roles in cancer that can potential therapeutic targets for intervention.